# Phase III, Efficacy and Safety of "Kamada-AAT for Inhalation"

> **NCT04204252** · PHASE3 · RECRUITING · sponsor: **Kamada, Ltd.** · enrollment: 220 (estimated)

## Conditions studied

- Alpha 1-Antitrypsin Deficiency

## Interventions

- **DRUG:** Alpha 1-Antitrypsin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04204252
- **Lead sponsor:** Kamada, Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2019-11-25
- **Primary completion:** 2028-12
- **Final completion:** 2031-06
- **Target enrollment:** 220 (ESTIMATED)
- **Last updated:** 2025-09-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04204252

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04204252, "Phase III, Efficacy and Safety of "Kamada-AAT for Inhalation"". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04204252. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*